CoChat

Story behind meldonium–from pharmacology to performance enhancement: a narrative review

Schobersberger, Wolfgang, Dünnwald, Tobias, Gmeiner, Günther, Blank, Cornelia · 2017 · British Journal of Sports Medicine

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Recent reports from the World Anti-Doping Agency (WADA) indicate an alarming prevalence in the use of meldonium among elite athletes. Therefore, in January 2016, meldonium was added to WADA's prohibited list after being monitored since 2015. Meldonium has been shown to have beneficial effects in cardiovascular, neurological and metabolic diseases due to its anti-ischaemic and cardioprotective properties, which are ascribed mainly to its inhibition of ß-oxidation and its activation of glycolysis. Despite its widespread use, there are only a few clinical studies or clinical trials available. Meldonium is registered in most Baltic countries and is easily accessible through the internet with no serious adverse effects reported by the manufacturer so far. Among athletes, meldonium is used with the purpose of increasing recovery rate or exercise performance. The benefit of taking meldonium in view of performance enhancement in athletes is quite speculative and is discussed without sound scientific evidence. This narrative review provides a detailed overview of the drug meldonium, focusing on the main topics pharmacology and biochemical actions, clinical applications, pharmacokinetics, methods of detection and potential for performance enhancement in athletes.

Overview

Integrity signals

Registry

Crossref · 10.1136/bjsports-2016-096357

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 68 references

Research works printed but not linked: 4

  1. 10.1042/bj3610417 · DOI · Paper page
  2. Heidemanis, 1990, Mildronate-plasma membrane interaction mechanisms, Proc Latv Acad Sci, 11, 108
  3. Dzerve, 2005, Mildronate improves peripheral circulation in patients with chronic heart failure: results of clinical trial (the first report), Sem Cardiol, 11, 56
  4. Kakhabrishvili, 2002, Effect of Mildronate on physical working capacity of highly qualified judoka, Ann Biomed Res Educ Tbilisi State Med Univ, 2, 263

Cited by

See all 61

Metadata

Authors
Schobersberger, W., Dünnwald, T., Gmeiner, G., & Blank, C.
Affiliations
  • UMIT TIROL - Private University for Health Sciences and Health Technology (AT)
  • Seibersdorf Laboratories (Austria) (AT)
Corresponding author
Schobersberger, Wolfgang
Venue
British Journal of Sports Medicine
Publisher
BMJ
Published
2016-07-27
Volume
51
Issue
1
Pages
22-25
ISSN
  • 0306-3674 (ISSN-L)
  • 1473-0480
OpenAlex
W2494230548
Cited by
61
References
68
Citations by year
2026: 4 · 2025: 7 · 2024: 9 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 2
FWCI
2.27
Type
journal article
Language
en
Open access
closed
Locations
  • British Journal of Sports Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Social Sciences › Sociology and Political Science › Doping in Sports
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Pharmacological Effects and Assays
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Sports Performance and Training
Keywords
meldonium, anti-doping, performance-enhancing drugs, athletes, pharmacology, pharmacokinetics, drug detection, beta-oxidation inhibition, cardioprotection, anti-ischemic effect
MeSH terms
Cardiovascular Diseases, Carnitine, Doping in Sports, Humans, Metabolic Diseases, Methylhydrazines, Nervous System Diseases, Athletic Performance, Athletes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Story behind meldonium–from pharmacology to performance enhancement: a narrative review. https://app.cochat.ai/papers/10.1136/bjsports-2016-096357
The paper
Schobersberger, W., Dünnwald, T., Gmeiner, G., & Blank, C. (2017). Story behind meldonium–from pharmacology to performance enhancement: a narrative review. British Journal of Sports Medicine. https://doi.org/10.1136/bjsports-2016-096357

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.